OncoMatch/Clinical Trials/NCT05241093
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Is NCT05241093 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies HYML-122; cytarabine for relapsed or refractory acute myeloid leukemia (aml).
Treatment: HYML-122; cytarabine — This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 mutation
Disease stage
Required: Stage RELAPSED, REFRACTORY
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: induction chemotherapy
Refractory to at least 1 cycle of induction chemotherapy. Relapsed after achieving remission with a prior therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05241093 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received induction chemotherapy.
Does this trial require FLT3?
Yes, FLT3 mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage RELAPSED or REFRACTORY is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages